JP2019213552A - オリゴ糖類の製造 - Google Patents
オリゴ糖類の製造 Download PDFInfo
- Publication number
- JP2019213552A JP2019213552A JP2019152682A JP2019152682A JP2019213552A JP 2019213552 A JP2019213552 A JP 2019213552A JP 2019152682 A JP2019152682 A JP 2019152682A JP 2019152682 A JP2019152682 A JP 2019152682A JP 2019213552 A JP2019213552 A JP 2019213552A
- Authority
- JP
- Japan
- Prior art keywords
- host microorganism
- human milk
- glycosidase
- lacto
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 154
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 153
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 39
- 244000005700 microbiome Species 0.000 claims abstract description 77
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims abstract description 76
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 56
- 235000020256 human milk Nutrition 0.000 claims abstract description 38
- 210000004251 human milk Anatomy 0.000 claims abstract description 37
- 239000000758 substrate Substances 0.000 claims abstract description 29
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
- 239000006227 byproduct Substances 0.000 claims abstract description 16
- 239000000543 intermediate Substances 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 37
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 36
- 230000015556 catabolic process Effects 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 235000000346 sugar Nutrition 0.000 claims description 34
- 230000037361 pathway Effects 0.000 claims description 29
- 150000002772 monosaccharides Chemical class 0.000 claims description 28
- 241000588724 Escherichia coli Species 0.000 claims description 27
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 25
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 24
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 24
- 229930182830 galactose Natural products 0.000 claims description 23
- 230000015572 biosynthetic process Effects 0.000 claims description 21
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 15
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 12
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 11
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 10
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 8
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 8
- 239000013067 intermediate product Substances 0.000 claims description 8
- -1 β-fucosidase Proteins 0.000 claims description 8
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 7
- 102000002464 Galactosidases Human genes 0.000 claims description 7
- 108010093031 Galactosidases Proteins 0.000 claims description 7
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 6
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 6
- 102000005348 Neuraminidase Human genes 0.000 claims description 6
- 108010006232 Neuraminidase Proteins 0.000 claims description 6
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 6
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 5
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 5
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 5
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 5
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 4
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 4
- 102000004366 Glucosidases Human genes 0.000 claims description 4
- 108010056771 Glucosidases Proteins 0.000 claims description 4
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 3
- 241000235088 Saccharomyces sp. Species 0.000 claims description 3
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 claims description 3
- 238000011437 continuous method Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 2
- 102000002268 Hexosaminidases Human genes 0.000 claims description 2
- 108010000540 Hexosaminidases Proteins 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 108010054377 Mannosidases Proteins 0.000 claims description 2
- 102000001696 Mannosidases Human genes 0.000 claims description 2
- QUOQJNYANJQSDA-MHQSSNGYSA-N Sialyllacto-N-tetraose a Chemical compound O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](OC2[C@H]([C@H](OC3[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@@H]1O QUOQJNYANJQSDA-MHQSSNGYSA-N 0.000 claims description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 claims description 2
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 2
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 2
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 2
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 2
- 108010055059 beta-Mannosidase Proteins 0.000 claims description 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims 1
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 claims 1
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 claims 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 claims 1
- 229930187173 lacto-N-Difucosylhexaose Natural products 0.000 claims 1
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 claims 1
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 4
- 230000001851 biosynthetic effect Effects 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 description 59
- 230000004151 fermentation Effects 0.000 description 59
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 49
- 239000008101 lactose Substances 0.000 description 46
- 239000002609 medium Substances 0.000 description 34
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 22
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 22
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 239000013598 vector Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000000813 microbial effect Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 10
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- RJTOFDPWCJDYFZ-SPVZFZGWSA-N Lacto-N-triaose Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O RJTOFDPWCJDYFZ-SPVZFZGWSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 3
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 3
- 102100040648 L-fucose kinase Human genes 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 241000080590 Niso Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000006652 catabolic pathway Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108010083136 fucokinase Proteins 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000004313 iron ammonium citrate Substances 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 101100075927 Aspergillus aculeatus mndA gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101100022282 Escherichia coli O157:H7 manC2 gene Proteins 0.000 description 2
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 2
- 101150102398 Galt gene Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 description 2
- PTVXQARCLQPGIR-SXUWKVJYSA-N beta-L-fucose 1-phosphate Chemical compound C[C@@H]1O[C@H](OP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O PTVXQARCLQPGIR-SXUWKVJYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 229960004642 ferric ammonium citrate Drugs 0.000 description 2
- 101150002054 galE gene Proteins 0.000 description 2
- 101150045500 galK gene Proteins 0.000 description 2
- 101150054547 galM gene Proteins 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 101150106565 gmd gene Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 description 2
- 101150001899 lacY gene Proteins 0.000 description 2
- 229930193965 lacto-N-fucopentaose Natural products 0.000 description 2
- 101150088678 manB gene Proteins 0.000 description 2
- 101150032120 manC gene Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- TXCIAUNLDRJGJZ-UHFFFAOYSA-N CMP-N-acetyl neuraminic acid Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-UHFFFAOYSA-N 0.000 description 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PSJVAGXZRSPYJB-UUXGNFCPSA-N Lacto-N-difucohexaose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H](CO)[C@H]([C@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)NC(C)=O)[C@@H](O[C@@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)C=O)O[C@@H]1[C@H](O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PSJVAGXZRSPYJB-UUXGNFCPSA-N 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101100168102 Yersinia pseudotuberculosis colC gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- FCIROHDMPFOSFG-LAVSNGQLSA-N disialyllacto-N-tetraose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)C(O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 FCIROHDMPFOSFG-LAVSNGQLSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 101150041441 fcl gene Proteins 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229930187367 lacto-N-difucohexaose Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/20—Preparation of compounds containing saccharide radicals produced by the action of an exo-1,4 alpha-glucosidase, e.g. dextrose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
発酵により生じたラクト−N−テトラオースおよびラクトースをともに10mMの濃度で含む溶液に、β−ガラクトシダーゼを添加した。50units/mL(最終濃度)のβ−ガラクトシダーゼ(Sigma−Aldrich Chemie GmbH社(Munich、ドイツ)、カタログ番号G6008)を加えて、ラクトースをグルコースおよびガラクトースへと分解し、糖類のクロマトグラフ分離(例えば、サイズ依存性のゲル濾過クロマトグラフィーによる分離)を良好に行った。ラクトースは数秒以内に切断され単糖類であるガラクトースおよびグルコースに分解されたのに対し、ラクト−N−テトラオースはそのまま残っていたことが示された(図1も参照のこと)。これらの実験によって、精製されたE.coli β−ガラクトシダーゼが高い選択性を有する、すなわちGal(β1−4)Glcグリコシド結合のみを選択的に加水分解し、ラクト−N−テトラオースの非還元末端に存在するGal(β1−3)GlcNAcグリコシド結合を加水分解しないことが証明された。図1Aは、10mMラクトースおよび10mMラクト−N−テトラオースのHPLCクロマトグラム(標準)を重ね書きしたものを示し、図1Bは、酵素を添加した直後に採取した、10mMラクトースおよび10mMラクト−N−テトラオースを含むβ−ガラクトシダーゼ反応液のHPLCクロマトグラムを示す。図1Cは、酵素の添加から3時間後に採取した、10mMラクトースおよび10mMラクト−N−テトラオースを含むβ−ガラクトシダーゼ反応液のHPLCクロマトグラムを示す。
2’−フコシルラクトース製造のためのフェドバッチ発酵は、組換え2’−フコシルラクトース合成E.coli菌株(E.coli BL21(DE3)ΔlacZ、ゲノム上の強力な構成型テトラサイクリン系プロモーターの制御下に、wbgL遺伝子(EP 11 1151 571.4)によりコードされる2’−フコシルトランスフェラーゼと、E.coli由来lacY、manB、manC、gmd、およびfclの各コピーとが組み込まれた菌株であり、さらにgalM、galK、galT、およびgalEを有する機能的なgalオペロンを含む;図10を参照のこと;フォワードプライマーP−TTACTCAGCAATAAACTGATATTCCGTCAGGCTGG(配列番号2);リバースプライマーP−TTGATAATCTCGCGCTCTTCAGCAGTCAGACTTTCCATATAGAGCGTAATTTCCGTTAACGTCGGTAGTGCTGACCTTGCCGGAGG(配列番号3))を使用し、該菌株を、所定の塩培地(7g/L NH4H3PO4、7g/L K2HPO4、2g/L KOH、0.37g/Lクエン酸、1mL/L消泡剤(Struktol J673、Schill+Seilacher)、1mM CaCl2、4mM MgSO4、ならびに0.101g/Lニトリロ三酢酸(pH6.5)、0.056g/Lクエン酸第二鉄アンモニウム、0.01g/L MnCl2・4H2O、0.002g/L CoCl2・6H2O、0.001g/L CuCl2・2H2O、0.002g/Lホウ酸、0.009g/L ZnSO4・7H2O、0.001g/L Na2MoO4・2H2O、0.002g/L Na2SeO3、および0.002g/L NiSO4・6H2Oからなる微量元素、ならびに炭素源として2%グリセロール)中で増殖させた。グリセロール供給液の構成は、800g/Lグリセロール、2.64g/L MgSO4、および4mL/L微量元素溶液であった。2’−フコシルラクトースが生成されるように、216g/Lラクトースを供給した。pHはアンモニア溶液(25%、v/v)を用いて制御し、該アンモニア溶液は、窒素源としての役割も果たした。2’−フコシルラクトースを製造するために、ラクトースを前駆体として供給した。フェドバッチ培養を一定の通気と撹拌の下、30℃で90時間行った。発酵開始90時間後には、添加したラクトースの大部分が2’−フコシルラクトースに変換された。
2’−フコシルラクトースの連続合成は2つの発酵槽を用いて達成された。発酵槽1には、ラクトース分解能欠損株である2’−フコシルラクトース発酵菌株(E.coli BL21(DE3)ΔlacZ、ゲノム上の強力な構成型テトラサイクリン系プロモーターの制御下に、wbgL遺伝子(EP 11 1151 571.4)によりコードされる2’−フコシルトランスフェラーゼと、E.coli由来lacY、manB、manC、gmd、およびfclの各コピーとが組み込まれた菌株であり、さらにgalM、galK、galT、およびgalEを有する機能的なgalオペロン(図10を参照のこと)を含む)を収容した。発酵槽2には、β−ガラクトシダーゼをコードする遺伝子E.coli由来lacZが発現していることを除いては、発酵槽1で使用した2’−フコシルラクトース発酵菌株と遺伝学的に同一の出発培養物を収容した(図5に記載の装置を参照のこと)。両発酵槽には、所定の塩培地を使用した。該塩培地は、7g/L NH4H3PO4、7g/L K2HPO4、2g/L KOH、0.37g/Lクエン酸、1ml/L消泡剤(Struktol J673、Schill+Seilacher)、1mM CaCl2、4mM MgSO4、ならびに0.101g/Lニトリロ三酢酸(pH 6.5)、0.056g/Lクエン酸第二鉄アンモニウム、0.01g/L MnCl2・4H2O、0.002g/L CoCl2・6H2O、0.001g/L CuCl2・2H2O、0.002g/Lホウ酸、0.009g/L ZnSO4・7H2O、0.001g/L Na2MoO4・2H2O、0.002g/L Na2SeO3、および0.002g/L NiSO4・6H2Oからなる微量元素、ならびに基質としての10mMラクトースおよび炭素源としての2%グリセロールを含む。
ラクトースをラクト−N−テトラオースへと発酵させる際、添加した基質以外に、ラクト−N−トリオース II(LNT−2)も蓄積する可能性がある。ラクト−N−テトラオースを精製するためのより経済的な発酵ろ液を得るために、ラクトースおよびLNT−2を特異的に分解することが望ましいことがわかった。
Claims (11)
- 宿主微生物を使用したヒトミルクオリゴ糖の製造方法であって、該ヒトミルクオリゴ糖が前記宿主微生物に天然に存在するものではなく、
a)所望のヒトミルクオリゴ糖の産生に適した宿主微生物を、該ヒトミルクオリゴ糖の産生が許容される条件下および培地中で培養し、それによって(イ)該ヒトミルクオリゴ糖、または(ロ)該ヒトミルクオリゴ糖、ならびに、該ヒトミルクオリゴ糖以外に糖生合成中間体および/もしくは副産物が生成される工程、
b)前記宿主微生物を培養している培地中でグリコシダーゼを使用し、糖生合成中間体および/または糖副産物および/または残った糖基質を分解する工程、ならびに
c)所望のヒトミルクオリゴ糖を回収する工程
を含み、
前記グリコシダーゼが、
前記宿主微生物によって内因的に生成されるものであり、内因的に生成される該グリコシダーゼをコードする核酸配列が、前記宿主細胞に天然に存在するものではなく、前記宿主細胞が、該宿主細胞に天然に存在しないグリコシダーゼを発現するよう安定的に形質転換されたものであり、宿主微生物内における該グリコシダーゼの発現が、誘導可能なものであることを特徴とする、
ヒトミルクオリゴ糖の製造方法。 - バッチ法または連続法である、請求項1に記載の方法。
- 培養宿主微生物の上清からヒトミルクオリゴ糖が回収され、該上清が、培養宿主微生物を遠心して上清と宿主微生物ペレットとに分離することにより得られることを特徴とする、請求項1または2に記載の方法。
- 所望の前記ヒトミルクオリゴ糖が、2’−フコシルラクトース、3−フコシルラクトース、2’,3−ジフコシルラクトース、3’−シアリルラクトース、6’−シアリルラクトース、3−フコシル−3’−シアリルラクトース、ラクト−N−テトラオース、ラクト−N−ネオテトラオース、ラクト−N−フコペンタオース I、ラクト−N−フコペンタオース II、ラクト−N−フコペンタオース III、ラクト−N−フコペンタオース V、ラクト−N−ジフコシルヘキサオース I、ラクト−N−ジフコシルヘキサオース II、ならびにラクト−N−シアリルペンタオース LSTa、LSTb、およびLSTcから選択され、具体的には図11の表1に示されるヒトミルクオリゴ糖類またはそれらの誘導体から選択されることを特徴とする、前記請求項のいずれかに記載の方法。
- 前記グリコシダーゼが、ガラクトシダーゼ、マンノシダーゼ、フコシダーゼ、シアリダーゼ(ノイラミニダーゼ)、グルコシダーゼ、N−アセチルグルコアミダーゼ、N−アセチルヘキソアミダーゼからなる群から選択される1以上であることを特徴とする、請求項1〜4のいずれかに記載の方法。
- 前記グリコシダーゼが、β−ガラクトシダーゼ、α−ガラクトシダーゼ、β−N−アセチルグルコアミダーゼ、β−N−アセチルヘキソアミダーゼ、β−マンノシダーゼ、α−マンノシダーゼ、α−フコシダーゼ、β−フコシダーゼ、β−グルコシダーゼ、α−グルコシダーゼ、ノイラミニダーゼからなる群から選択される1以上であることを特徴とする、請求項1〜4のいずれかに記載の方法。
- 前記宿主微生物が細菌および酵母から選択されることを特徴とする、請求項1〜6のいずれかに記載の方法。
- 前記宿主微生物がEscherichia coli菌株、Lactobacillus種、もしくはCorynebacterium glutamicum菌株、またはSaccharomyces sp. 菌株であることを特徴とする、請求項1〜7のいずれかに記載の方法。
- 用いられる前記宿主微生物が、本来それ自体に存在しない糖異化経路タンパク質を発現しており、該タンパク質が、ガラクトシダーゼを使用する場合におけるガラクトース異化経路タンパク質、フコシダーゼを使用する場合におけるフコース異化経路タンパク質、β−N−アセチルヘキソサミニダーゼを使用するN−アセチルグルコサミン異化経路タンパク質の少なくとも1つから選択されることを特徴とする、請求項1〜8のいずれかに記載の方法。
- 用いられる前記宿主微生物において、分解中に遊離される単糖類を変換するために、単糖類サルベージ経路を過剰発現させることを特徴とする、請求項1〜8のいずれかに記載の方法。
- 用いられる前記宿主微生物が、糖異化経路タンパク質を発現する野生株であり、該タンパク質が、ガラクトシダーゼを使用する場合におけるガラクトース異化経路タンパク質、フコシダーゼを使用する場合におけるフコース異化経路タンパク質、β−N−アセチルヘキソサミニダーゼを使用するN−アセチルグルコサミン異化経路タンパク質の少なくとも1つから選択され、このようなタンパク質を、前記方法または前記使用の際に前記宿主微生物内に過剰発現させることを特徴とする、請求項1〜10のいずれかに記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13183670.2A EP2845905B8 (en) | 2013-09-10 | 2013-09-10 | Production of oligosaccharides |
EP13183670.2 | 2013-09-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016541849A Division JP6894703B2 (ja) | 2013-09-10 | 2014-07-04 | オリゴ糖類の製造 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019213552A true JP2019213552A (ja) | 2019-12-19 |
JP6992029B2 JP6992029B2 (ja) | 2022-01-13 |
Family
ID=49117764
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016541849A Active JP6894703B2 (ja) | 2013-09-10 | 2014-07-04 | オリゴ糖類の製造 |
JP2019152702A Active JP7389584B2 (ja) | 2013-09-10 | 2019-08-23 | オリゴ糖類の製造 |
JP2019152682A Active JP6992029B2 (ja) | 2013-09-10 | 2019-08-23 | オリゴ糖類の製造 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016541849A Active JP6894703B2 (ja) | 2013-09-10 | 2014-07-04 | オリゴ糖類の製造 |
JP2019152702A Active JP7389584B2 (ja) | 2013-09-10 | 2019-08-23 | オリゴ糖類の製造 |
Country Status (11)
Country | Link |
---|---|
US (3) | US11427845B2 (ja) |
EP (3) | EP2845905B8 (ja) |
JP (3) | JP6894703B2 (ja) |
KR (1) | KR102335067B1 (ja) |
CN (5) | CN118028397A (ja) |
AU (1) | AU2014320757C1 (ja) |
BR (1) | BR112016005228A8 (ja) |
DK (1) | DK2845905T3 (ja) |
ES (1) | ES2875327T3 (ja) |
PL (1) | PL2845905T3 (ja) |
WO (1) | WO2015036138A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2845905B8 (en) * | 2013-09-10 | 2021-07-14 | Chr. Hansen HMO GmbH | Production of oligosaccharides |
PL2896628T3 (pl) | 2014-01-20 | 2019-03-29 | Jennewein Biotechnologie Gmbh | Sposób wydajnego oczyszczania obojętnych oligosacharydów ludzkiego mleka (HMO) z fermentacji mikrobiologicznej |
CN107530366A (zh) * | 2015-03-31 | 2018-01-02 | 格礼卡姆股份公司 | 包含3’‑o‑唾液乳糖的人乳寡糖的混合物 |
US10829508B2 (en) | 2015-12-18 | 2020-11-10 | Glycom A/S | Fermentative production of oligosaccharides |
EP3445770A4 (en) | 2016-04-19 | 2020-03-18 | Glycom A/S | SEPARATION OF OLIGOSACCHARIDES FROM A FERMENTATION BROTH |
CN109414447A (zh) | 2016-06-24 | 2019-03-01 | 格礼卡姆股份公司 | 包括hmo的组合物、其制备和用于预防和/或治疗病毒和/或细菌感染的用途 |
CN106190938B (zh) * | 2016-07-18 | 2019-05-14 | 南开大学 | 一种构建的重组大肠杆菌及生物合成3’-唾液乳糖的方法 |
WO2018020473A1 (en) * | 2016-07-28 | 2018-02-01 | Fonterra Co-Operative Group Limited | Dairy product and process |
IL290057B2 (en) * | 2016-09-19 | 2023-09-01 | Prolacta Bioscience Inc | Pure preparations of oligosaccharides of breast milk |
EP3315610B1 (en) * | 2016-10-29 | 2020-12-16 | Jennewein Biotechnologie GmbH | Process for the production of fucosylated oligosaccharides |
FI3821712T3 (fi) | 2017-01-13 | 2023-01-13 | Parannetulla menetelmällä saatu hapatettu maitotuote | |
JP2018140968A (ja) * | 2017-02-28 | 2018-09-13 | 日本食品化工株式会社 | 1,6−アンヒドロ−β−D−グルコフラノース含有糖質の製造方法 |
DK3375291T3 (da) | 2017-03-17 | 2022-10-31 | Chr Hansen Hmo Gmbh | Fremgangsmåde til hæmning af isomerisering af et reducerende saccharid efter termisk behandling |
WO2019003135A1 (en) * | 2017-06-30 | 2019-01-03 | Glycom A/S | PURIFICATION OF OLIGOSACCHARIDES |
EP3425052A1 (en) | 2017-07-07 | 2019-01-09 | Jennewein Biotechnologie GmbH | Fucosyltransferases and their use in producing fucosylated oligosaccharides |
US11505567B2 (en) | 2017-07-12 | 2022-11-22 | Glycom A/S | Amorphous mixture comprising a neutral mono- or oligosaccharide and an acidic non-carbohydrate component |
EP3494806A1 (en) | 2017-12-08 | 2019-06-12 | Jennewein Biotechnologie GmbH | Spray-dried lacto-n-fucopentaose |
EP3524067A1 (en) | 2018-02-08 | 2019-08-14 | Jennewein Biotechnologie GmbH | Spray-dried mixture of human milk oligosaccharides |
EP3494807A1 (en) | 2017-12-11 | 2019-06-12 | Jennewein Biotechnologie GmbH | Spray-dried sialyllactose |
KR20200096793A (ko) | 2017-12-08 | 2020-08-13 | 젠와인 바이오테크놀로지 게엠바하 | 분무건조된 사당류 |
EP3494805A1 (en) | 2017-12-08 | 2019-06-12 | Jennewein Biotechnologie GmbH | Spray-dried tetrasaccharides |
EP3494804A1 (en) | 2017-12-08 | 2019-06-12 | Jennewein Biotechnologie GmbH | Spray-dried 3-fucosyllactose |
EP3569713A1 (en) * | 2018-05-16 | 2019-11-20 | Jennewein Biotechnologie GmbH | Use of glycosidases in the production of oligosaccharides |
EP3799594A4 (en) * | 2018-05-23 | 2022-06-15 | DSM IP Assets B.V. | PRODUCTION OF OLIGOSACCHARIDS |
US10519475B1 (en) * | 2018-11-21 | 2019-12-31 | Amyris, Inc. | Biosynthesis of compounds in yeast |
PL3897902T3 (pl) * | 2018-12-19 | 2024-02-26 | Glycom A/S | Rozdzielanie oligosacharydów |
CN109735479B (zh) * | 2019-01-30 | 2022-04-01 | 光明乳业股份有限公司 | 一种合成2’-岩藻糖基乳糖的重组枯草芽孢杆菌及其构建方法与应用 |
JP7348675B2 (ja) * | 2019-05-21 | 2023-09-21 | 高麗大学校産学協力団 | α-及びβ-1,4-グリコシド結合を全て切断する酵素の用途 |
EP3979827B1 (en) * | 2019-06-04 | 2023-08-02 | N.V. Nutricia | Nutritional composition comprising 2'fucosyllactose and 3'galactosyllactose |
US20230068960A1 (en) | 2019-09-24 | 2023-03-02 | Prolacta Bioscience, Inc. | Compositions and methods for treatment of inflammatory and immune diseases |
CA3188645A1 (en) | 2020-08-14 | 2022-02-17 | Prolacta Bioscience, Inc. | Human milk oligosaccharide compositions for use with bacteriotherapies |
WO2022155201A1 (en) | 2021-01-12 | 2022-07-21 | Prolacta Bioscience, Inc. | Synbiotic treatment regimens |
DK202101233A1 (en) | 2021-12-21 | 2023-06-27 | Dsm Ip Assets Bv | Crystallization of LNnT |
CN114107342B (zh) * | 2021-12-27 | 2024-01-26 | 黄山同兮生物科技有限公司 | 一种去除发酵液中乳糖的方法 |
KR102616020B1 (ko) | 2021-12-31 | 2023-12-22 | 매일유업 주식회사 | 모유 올리고당 혼합물을 유효성분으로 포함하는 장관면역 개선용, 장 염증 예방 또는 개선용 조성물 |
CN116042562B (zh) * | 2022-03-11 | 2023-10-20 | 山东恒鲁生物科技有限公司 | 重组酵母菌及其应用 |
CN115011535A (zh) * | 2022-05-10 | 2022-09-06 | 南通励成生物工程有限公司 | 一种以葡萄糖为碳源合成2’-岩藻糖基乳糖的菌株及其构建方法和应用 |
KR20240002283A (ko) * | 2022-06-28 | 2024-01-05 | 주식회사 삼양사 | 2’-푸코실락토오스 제조방법 |
WO2024042235A1 (en) | 2022-08-25 | 2024-02-29 | Dsm Ip Assets B.V. | Hybrid method for producing complex hmos |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5995895A (ja) * | 1982-11-22 | 1984-06-02 | Meiji Seika Kaisha Ltd | フラクトオリゴ糖の精製法 |
JPH05276969A (ja) * | 1992-04-03 | 1993-10-26 | Nippon Shinyaku Co Ltd | 高純度マルトオリゴ糖の製法 |
JPH08140691A (ja) * | 1994-11-17 | 1996-06-04 | Meiji Seika Kaisha Ltd | 高濃度糖混合液からの高純度オリゴ糖類の製造法 |
WO2012097950A1 (en) * | 2011-01-20 | 2012-07-26 | Jennewein Biotechnologie Gmbh | Novel fucosyltransferases and their applications |
WO2012112777A2 (en) * | 2011-02-16 | 2012-08-23 | Glycosyn LLC | Biosynthesis of human milk oligosaccharides in engineered bacteria |
JP2012529274A (ja) * | 2009-06-08 | 2012-11-22 | イェンネワイン バイオテクノロジー ゲーエムベーハー | ヒトミルクオリゴ糖の合成 |
JP2013501504A (ja) * | 2009-08-07 | 2013-01-17 | イナルコ ソシエタ ペル アチオニ | 超高純度ガラクトオリゴ糖を製造する方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6391092A (ja) | 1986-10-07 | 1988-04-21 | Yakult Honsha Co Ltd | オリゴ糖の製造法 |
JPH07274990A (ja) | 1994-04-15 | 1995-10-24 | Mitsubishi Kasei Eng Co | 環状イヌロオリゴ糖の精製方法 |
KR100877278B1 (ko) * | 2000-11-16 | 2009-01-07 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | α-이소말토실 전이효소 활성을 가진 폴리펩티드 |
US20080145899A1 (en) * | 2004-09-17 | 2008-06-19 | Neose Technologies Inc | Production of Oligosaccharides By Microorganisms |
BRPI0810065A2 (pt) | 2007-04-16 | 2020-01-14 | Momenta Pharmaceuticals Inc | caracterização de n-glicanos usando exoglicosidases |
KR100945306B1 (ko) | 2007-12-31 | 2010-03-03 | 주식회사 삼양제넥스 | 고순도 갈락토올리고당의 제조방법 |
JP5455244B2 (ja) * | 2008-03-12 | 2014-03-26 | タタ ケミカルズ リミテッド | 遊離細胞によるガラクトオリゴ糖の製造方法 |
BRPI0923433B1 (pt) * | 2008-12-19 | 2021-06-01 | Jennewein Biotechnologie Gmbh | Método para produzir uma célula geneticamente modificada tendo a capacidade de produzir compostos fucosilados e método para fazer um composto fucosilado |
CN101870992A (zh) * | 2010-06-21 | 2010-10-27 | 天津科技大学 | 利用基因工程菌耦合发酵合成gdp-岩藻糖的方法 |
EP2944690B1 (en) | 2010-10-11 | 2017-12-20 | Jennewein Biotechnologie GmbH | Novel fucosyltransferases and their applications |
AU2012257395A1 (en) * | 2011-05-13 | 2013-12-12 | Glycom A/S | Method for generating human milk oligosaccharides (HMOs) or precursors thereof |
DK2728009T3 (da) * | 2012-10-31 | 2017-11-06 | Jennewein Biotechnologie Gmbh | Fremgangsmåde til fremstilling af monosaccharider |
EP2845905B8 (en) * | 2013-09-10 | 2021-07-14 | Chr. Hansen HMO GmbH | Production of oligosaccharides |
-
2013
- 2013-09-10 EP EP13183670.2A patent/EP2845905B8/en active Active
- 2013-09-10 ES ES13183670T patent/ES2875327T3/es active Active
- 2013-09-10 EP EP19184576.7A patent/EP3572521A1/en active Pending
- 2013-09-10 PL PL13183670T patent/PL2845905T3/pl unknown
- 2013-09-10 EP EP19184573.4A patent/EP3572520A1/en active Pending
- 2013-09-10 DK DK13183670.2T patent/DK2845905T3/da active
-
2014
- 2014-07-04 KR KR1020167008748A patent/KR102335067B1/ko active IP Right Grant
- 2014-07-04 CN CN202410094161.5A patent/CN118028397A/zh active Pending
- 2014-07-04 BR BR112016005228A patent/BR112016005228A8/pt not_active Application Discontinuation
- 2014-07-04 CN CN202410094021.8A patent/CN118028396A/zh active Pending
- 2014-07-04 CN CN201480061563.XA patent/CN105722991A/zh active Pending
- 2014-07-04 WO PCT/EP2014/064280 patent/WO2015036138A1/en active Application Filing
- 2014-07-04 CN CN201910957839.7A patent/CN110643658A/zh active Pending
- 2014-07-04 AU AU2014320757A patent/AU2014320757C1/en active Active
- 2014-07-04 JP JP2016541849A patent/JP6894703B2/ja active Active
- 2014-07-04 CN CN201910957609.0A patent/CN110628842A/zh active Pending
-
2016
- 2016-03-10 US US15/067,037 patent/US11427845B2/en active Active
-
2019
- 2019-08-23 JP JP2019152702A patent/JP7389584B2/ja active Active
- 2019-08-23 JP JP2019152682A patent/JP6992029B2/ja active Active
-
2022
- 2022-07-22 US US17/814,333 patent/US11981947B2/en active Active
- 2022-07-22 US US17/814,337 patent/US20220403433A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5995895A (ja) * | 1982-11-22 | 1984-06-02 | Meiji Seika Kaisha Ltd | フラクトオリゴ糖の精製法 |
JPH05276969A (ja) * | 1992-04-03 | 1993-10-26 | Nippon Shinyaku Co Ltd | 高純度マルトオリゴ糖の製法 |
JPH08140691A (ja) * | 1994-11-17 | 1996-06-04 | Meiji Seika Kaisha Ltd | 高濃度糖混合液からの高純度オリゴ糖類の製造法 |
JP2012529274A (ja) * | 2009-06-08 | 2012-11-22 | イェンネワイン バイオテクノロジー ゲーエムベーハー | ヒトミルクオリゴ糖の合成 |
JP2013501504A (ja) * | 2009-08-07 | 2013-01-17 | イナルコ ソシエタ ペル アチオニ | 超高純度ガラクトオリゴ糖を製造する方法 |
WO2012097950A1 (en) * | 2011-01-20 | 2012-07-26 | Jennewein Biotechnologie Gmbh | Novel fucosyltransferases and their applications |
WO2012112777A2 (en) * | 2011-02-16 | 2012-08-23 | Glycosyn LLC | Biosynthesis of human milk oligosaccharides in engineered bacteria |
Also Published As
Publication number | Publication date |
---|---|
EP2845905B8 (en) | 2021-07-14 |
US20220389468A1 (en) | 2022-12-08 |
JP6992029B2 (ja) | 2022-01-13 |
DK2845905T3 (da) | 2021-06-14 |
CN118028397A (zh) | 2024-05-14 |
JP2019213553A (ja) | 2019-12-19 |
KR102335067B1 (ko) | 2021-12-03 |
US11981947B2 (en) | 2024-05-14 |
JP7389584B2 (ja) | 2023-11-30 |
BR112016005228A8 (pt) | 2022-11-08 |
US20160186223A1 (en) | 2016-06-30 |
KR20160065111A (ko) | 2016-06-08 |
JP2016530888A (ja) | 2016-10-06 |
CN110643658A (zh) | 2020-01-03 |
PL2845905T3 (pl) | 2021-09-27 |
EP3572521A1 (en) | 2019-11-27 |
EP2845905A1 (en) | 2015-03-11 |
US20220403433A1 (en) | 2022-12-22 |
WO2015036138A1 (en) | 2015-03-19 |
AU2014320757A1 (en) | 2016-04-28 |
CN105722991A (zh) | 2016-06-29 |
EP2845905B1 (en) | 2021-05-19 |
AU2014320757C1 (en) | 2018-07-19 |
EP3572520A1 (en) | 2019-11-27 |
US11427845B2 (en) | 2022-08-30 |
ES2875327T3 (es) | 2021-11-10 |
BR112016005228A2 (ja) | 2017-09-05 |
AU2014320757B2 (en) | 2018-04-19 |
CN118028396A (zh) | 2024-05-14 |
JP6894703B2 (ja) | 2021-06-30 |
CN110628842A (zh) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6992029B2 (ja) | オリゴ糖類の製造 | |
Drouillard et al. | Efficient synthesis of 6′-sialyllactose, 6, 6′-disialyllactose, and 6′-KDO-lactose by metabolically engineered E. coli expressing a multifunctional sialyltransferase from the Photobacterium sp. JT-ISH-224 | |
US9902984B2 (en) | Fermentative production of oligosaccharides | |
EP3425052A1 (en) | Fucosyltransferases and their use in producing fucosylated oligosaccharides | |
EP2927316B1 (en) | Total fermentation of oligosaccharides | |
EP3569713A1 (en) | Use of glycosidases in the production of oligosaccharides | |
WO2017101958A1 (en) | Fermentative production of oligosaccharides | |
JP6165872B2 (ja) | 単糖類の製造方法 | |
CN110637091B (zh) | 利用源自舞蹈拟土地杆菌的岩藻糖基转移酶的2’-岩藻糖基乳糖的生产方法 | |
DK180952B1 (en) | A dfl-producing strain | |
DK181497B1 (en) | ENHANCING FORMATION OF THE HMOS LNT AND/OR LNnT BY MODIFYING LACTOSE IMPORT IN THE CELL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211027 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6992029 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |